207P - Impact of K-RAS mutation status on disease behavior and treatment outcome in metastatic colorectal cancer patients

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Colon and Rectal Cancer
Rectal Cancer
Translational Research
Presenter Ayman Rasmy
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors A. Rasmy1, A. Fayed2, S. Fouad3
  • 1Medical Oncology Department, Zagazig University Faculty of Medicine, 11111 - Zagazig/EG
  • 2Clinical Oncology, Zagazig University, 11111 - Zagazig/EG
  • 3Internal Medicine, Zagazig University, 11111 - Zagazig/EG



Over the last 20years, significant improvements have been reported in the treatment outcomes of metastatic colorectal cancer (mCRC).In the molecular-based intervention era, the study of K-RAS mutation status is very important, especially for personalized therapy.Indeed, the median survival of mCRC patients is now approximately 24months(mo.), rather than 12 mo.


This retrospective study analysed the clinical, radiological and laboratory data of 360 mCRC patients(pts) diagnosed at the King Fahad Specialist Hospital Dammam, Saudi Arabia and Zagazig University from Feb. 2011 to Dec. 2015.Chemotherapy primarily included oxaliplatin or irinotecan based combination. Bevacizumab was added for wild-type and mutant K-RAS pts without contraindications, whereas cetuximab was used only for wild-type.Palliative surgery was performed for some obstruction/perforation cases.Treatment response, relapse/progression time and disease-related mortality were evaluated.Limited K-RAS mutation status (exon12,13) was tested for in all pts. The primary aim was to determine the effect of K-RAS mutation status on mCRC disease outcome.


Of the 360 pts,65.6% were male and 55% were between age 40–60 years.Wild-type K-RAS was detected in 61.1% pts and mutant K-RAS in 38.9% pts. Most left-sided colon tumours had mutant K-RAS; right-sided colon tumours showed less frequent K-RAS mutations(p 


In mCRC patients, those with the mutant K-RAS form of the disease had an aggressive presentation. Mutant K-RAS patients had poor DFS and OS. Understanding of the factors that regulate K-RAS expression may lead to a new effective therapeutic strategy.

Clinical trial indentification

It is retrospective trial

Legal entity responsible for the study





All authors have declared no conflicts of interest.